This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Athersys Announces Initiation Of Patient Enrollment For Phase II Clinical Trial In Inflammatory Bowel Disease

CLEVELAND, March 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the initiation of patient enrollment, and dosing of the first patient for a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem ®, Athersys' allogeneic cell therapy product for the treatment of ulcerative colitis (UC). This Phase II clinical trial is part of a strategic global collaboration between Athersys and Pfizer Inc. (NYSE:PFE) to investigate MultiStem for the treatment of inflammatory bowel disease (IBD).

The Phase II study is a randomized, double-blind, placebo-controlled, multi-center study designed to investigate the safety and efficacy of MultiStem in subjects with moderate to severe UC. The trial will be conducted at multiple clinical sites in North America and Europe, and is expected to include up to approximately 126 patients. Individuals participating in the study will receive multiple doses of either MultiStem or placebo, administered over a period of several weeks. Primary safety and efficacy endpoints will include endoscopic evaluation at baseline and at eight weeks, with a follow-up of all patients through twelve months.   

"Despite treatment advances in recent years, Inflammatory Bowel Disease remains a debilitating condition for many individuals, and represents an area of substantial unmet medical need," said Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer of Athersys. "We're pleased with the continued progress of our partnership with Pfizer and excited about commencing the trial."

Dr. Ruth McKernan, Head of Pfizer Regenerative Medicine, added: "Both teams have worked very well together, and we are pleased to be commencing this Phase II trial in this innovative area."

About Inflammatory Bowel Disease

According to Datamonitor, more than two million individuals in the United States, core European markets and Japan suffer from various forms of IBD, including Crohn's Disease and UC, which is the most commonly diagnosed form of IBD. UC is a chronic, relapsing inflammatory condition involving all or a portion of the colon. Patients with UC most commonly present with diarrhea, urgency, rectal bleeding, and abdominal pain. Patients may also experience fatigue, fevers, weight loss, and dehydration. The symptoms can be incapacitating.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.00 1.50%
FB $117.81 -0.64%
GOOG $694.49 -0.53%
TSLA $235.35 -2.70%
YHOO $36.06 -1.30%


Chart of I:DJI
DOW 17,733.58 -157.58 -0.88%
S&P 500 2,059.67 -21.76 -1.05%
NASDAQ 4,762.1030 -55.4910 -1.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs